Recent Developments and Novel Drug Delivery Strategies for the Treatment of Tuberculosis
DOI:
https://doi.org/10.37285/ijpsn.2019.12.3.2Abstract
Tuberculosis (TB) is a contagious infectious illness caused by species having a place with the Mycobacterium tuberculosis complex. The clinical management of tuberculosis still remains a difficult task. Treatment of TB with anti-tubercular drugs becomes the only option available. Hence, the goals of treatment are ensure cure without relapse, prevent death, impede transmission, and prevent emergence of drug resistant strains. This review describes the latest developments and innovative drug delivery strategies for treatment of TB in order to improve the therapeutic efficacy and reduce toxic effect of anti-tubercular agents and enhance patient compliance with concomitant decrease in drug interaction. Among different novel drug delivery systems Niosomes, Liposomes, Dendrimers, Cyclodextrins, Microencapsulation, Alginates and Hydrogels have been described as new drug delivery strategies of anti-tubercular agents.
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
Keywords:
Tuberculosis, Anti-tubercular Drugs, Drug Delivery, Therapeutic efficacy, Toxic effect, Clinical trials
Downloads
Published
2019-05-31
How to Cite
1.
Brhane Y, Gabriel T, Adane T, Negash Y, Mulugeta H, Ayele M. Recent Developments and Novel Drug Delivery Strategies for the Treatment of Tuberculosis. Scopus Indexed [Internet]. 2019 May 31 [cited 2024 Jul. 27];12(3):4524-30. Available from: http://ijpsnonline.com/index.php/ijpsn/article/view/298
Issue
Section
Review Articles
References
Agnihotri N, Mishra R, Goda C, and Arora M (2012). Microencapsulation–A Novel Approach in Drug Delivery: A Review. Journal of Pharmaceutical Sciences 2: 1-20.
Anjana MN, Nair SC and Joseph J (2013). An updated review of cyclodextrins -an enabling technology for challenging pharmaceutical formulations. International Journal of Pharmacy and Pharmaceutical Sciences 5: 54-58.
Challa R, Ahuja A, Ali J, and Khar RK (2005). Cyclodextrins in Drug Delivery: An Updated Review. AAPS PharmSciTech 6: E329-E355.
Chetty S, Ramesh M, Singh PA, and Soliman MES (2017). Recent advancements in the development of anti-tuberculosis drugs. Bioorganic and Medicinal Chemistry Letters 27: 370-386.
Ding BS, Dziubla T, Shuvaev VV, Muro S, and Muzykantov VR (2006). Advanced drug delivery systems that target the vascular endothelium. Mol Interv 6: 98-112.
Ghavami G and Sardari S (2011). New chimeric anti-tubercular dendrimers with self- delivering property. African Journal of Microbiology Research 5: 2550-2554.
Godebo A, Abiy H, and Toma A (2015). Recent Advances in the Development of Anti-tuberculosis Drugs Acting on Multidrug-Resistant Strains: A review. International Journal of Research in Pharmacy and Biosciences 2: 1-18.
Gupta A, and Dey B (2012). Microencapsulation for controlled drug delivery: a comprehensive review. Sunsari Technical College Journal 1: 48-54.
Guzman JD, Rincón XM, and Ribón W (2013). Research and Development of New Drugs against Tuberculosis. In Tuberculosis-Current Issues in Diagnosis and Management, InTech Publisher, pp 332-358.
Hillery AM, Lioyd AW and Swarbrick J (eds) (2001). Drug Delivery and Targeting; for Pharmacists and Pharmaceutical Scientists, 1st ed, Taylor & Francis, London and New York.
Hua S, and Wu SY (2013). The use of lipid-based nanocarriers for targeted pain therapies. Front Pharmacol 4: 143.
Jawahar N, and Reddy G (2012). Nanoparticles: A Novel Pulmonary Drug Delivery System for Tuberculosis. Journal of pharmaceutical science and research 4: 1901-1906.
Khuller GK, Kapur M, and Sharma S (2004). Liposome technology for drug delivery against mycobacterial infections. Current Pharmaceutical Design 10: 3263-3274.
Koning GA and Storm G (2003). Targeted drug delivery systems for the intracellular delivery of macromolecular drugs. Drug Discov Today 8: 482-483.
Lienhardt C, Vernon A, and Raviglione MC (2010). New drugs and new regimens for the treatment of tuberculosis: Review of the drug development pipeline and implications for national programmes. Current Opinion in Pulmonary Medicine 16: 186-193.
Liua Y, Matsumotob M, Ishidac H, Ohguroc K, Yoshitakea M, Guptaa R, Geitera L, and Hafkin J (2018). Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Tuberculosis 111: 20-30.
Mahajan R (2013). Bedaquiline: First FDA-Approved Tuberculosis Drug in 40 Years. Int J Appl Basic Med Res 3: 1-2.
Metselaar JM, and Storm G (2005). Liposomes in the treatment of inflammatory disorders. Expert Opin. Drug Deliv 2: 465-76.
Moghassemia S and Hadjizadeh A (2014). Nano-niosomes as nanoscale drug delivery systems: An illustrated review. Journal of Controlled Release 185: 22-36.
Mohan A, D Kumar DP and Harikrishna J (2012). Newer anti-TB Drugs and Drug Delivery Systems. In Therapeutics, Medicine update, pp 388-392.
Muzzalupo R and Tavano L (2015). Niosomal drug delivery for transdermal targeting: recent advances. Research and Reports in Transdermal Drug Delivery 4: 23-33.
Nagda D, Rathore KS, Bharkatiya M, Sisodia SS, and Nema RK (2010). Bucky balls: A novel drug delivery system. Journal of Chemical and Pharmaceutical Research 2: 240 248.
Nasiruddin M, Neyaz MK, and Das S (2017). Nanotechnology-Based Approach in Tuberculosis Treatment. Tuberculosis Research and Treatment 2017: 1-12.
Olaru ID, Groote-Bidlingmaier FV, Heyckendorf J, Yew WW, Lange C and Chang KC (2015). Novel drugs against tuberculosis: A clinician’s perspective. European Respiratory Journal 45: 1119-1131.
Pandey R and Khuller GK (2006). Nanotechnology based drug delivery system(s) for the management of tuberculosis. Indian Journal of Experimental Biology 44: 357-366.
Pawar SN and Edgar KJ (2012). Alginate derivatization: A review of chemistry, properties and applications. Biomaterials 33: 3279-3305.
Rawal T and Butani S (2016). Combating Tuberculosis Infection: A Forbidding Challenge. Indian Journal of Pharmaceutical Sciences 78: 8-16.
Roy SD, Nandy S, and Banerjee S (2012). Microencapsulation: Convenient Mode of Drug Delivery in Novel Drug Delivery System. International Journal of Pharmacy and Life Sciences 3: 1555–1562.
Sacksteder KA, Protopopova M, Barry CE, Andries K and Nacy C (2012). A discovery and development of sq109: a new antitubercular drug with a novel mechanism of action. Future Microbiol 7: 823-837.
Sankhyan A and Pawar P (2012). Recent trends in Niosome as vesicular drug delivery system. Journal of Applied Pharma-ceutical Science 2: 20-32.
Shafiq N, Kondel R, and Malhotra S (2013). Tuberculosis and Nanotechnology: Where shall the Twain meet? Journal of Postgraduate Medicine Education and Research 47: pp. 188-192.
Smith JP (2011). Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis. Yale Journal of Biology and Medicine 84: 361-369.
Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, Fischer E, Barnes SW, Walker J R, Alland D, Barry CE and Boshoff, HI (2012). SQ109 targets mmpl3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of mycobacterium tuberculosis. Antimicrob Agents Chemother 56: 1797-1809.
Tiwari RK, Singh L, and Sharma V (2013). Alginate Micro-Beads in Novel Drug Delivery System: an Overview. International science press 5: 1-13.
Toosky M and Javid B (2014). Novel diagnostics and therapeutics for drug-resistant tuberculosis. British Medical Bulletin 110: 129-140.
Varun T, Sonia A, Bharat P, and Patil V (2012). Niosomes and liposomesVescicular approach towards Transdermal drug delivery. International journal of pharmaceutical and chemical sciences 1: 981-993.
Vashist A, Kaushik A, Vashist A, Jayant RD, Tomitaka A, Ahmad S, Gupta YK, and Nair M (2016). Recent trends on hydrogel based drug delivery systems for infectious diseases. Biomaterials Science 4: 1535-1553.
Vedha Hari BN, Chitra KP, Bhimavarapu R, Karunakaran P, Muthukrishnan M, and Rani BS (2010). Novel technologies: A weapon against tuberculosis. Indian Journal of Pharmacology 42: 338-344.
Zimmerman SC, and Lawless LJ (2001). Supramolecular Chemistry of Dendrimers. In Topics in Current Chemistry, Springer-Verlag Berlin Heidelberg, pp. 95-120.
Zumla A, Nahid P, Cole ST (2013). Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 12: 388-404.
Anjana MN, Nair SC and Joseph J (2013). An updated review of cyclodextrins -an enabling technology for challenging pharmaceutical formulations. International Journal of Pharmacy and Pharmaceutical Sciences 5: 54-58.
Challa R, Ahuja A, Ali J, and Khar RK (2005). Cyclodextrins in Drug Delivery: An Updated Review. AAPS PharmSciTech 6: E329-E355.
Chetty S, Ramesh M, Singh PA, and Soliman MES (2017). Recent advancements in the development of anti-tuberculosis drugs. Bioorganic and Medicinal Chemistry Letters 27: 370-386.
Ding BS, Dziubla T, Shuvaev VV, Muro S, and Muzykantov VR (2006). Advanced drug delivery systems that target the vascular endothelium. Mol Interv 6: 98-112.
Ghavami G and Sardari S (2011). New chimeric anti-tubercular dendrimers with self- delivering property. African Journal of Microbiology Research 5: 2550-2554.
Godebo A, Abiy H, and Toma A (2015). Recent Advances in the Development of Anti-tuberculosis Drugs Acting on Multidrug-Resistant Strains: A review. International Journal of Research in Pharmacy and Biosciences 2: 1-18.
Gupta A, and Dey B (2012). Microencapsulation for controlled drug delivery: a comprehensive review. Sunsari Technical College Journal 1: 48-54.
Guzman JD, Rincón XM, and Ribón W (2013). Research and Development of New Drugs against Tuberculosis. In Tuberculosis-Current Issues in Diagnosis and Management, InTech Publisher, pp 332-358.
Hillery AM, Lioyd AW and Swarbrick J (eds) (2001). Drug Delivery and Targeting; for Pharmacists and Pharmaceutical Scientists, 1st ed, Taylor & Francis, London and New York.
Hua S, and Wu SY (2013). The use of lipid-based nanocarriers for targeted pain therapies. Front Pharmacol 4: 143.
Jawahar N, and Reddy G (2012). Nanoparticles: A Novel Pulmonary Drug Delivery System for Tuberculosis. Journal of pharmaceutical science and research 4: 1901-1906.
Khuller GK, Kapur M, and Sharma S (2004). Liposome technology for drug delivery against mycobacterial infections. Current Pharmaceutical Design 10: 3263-3274.
Koning GA and Storm G (2003). Targeted drug delivery systems for the intracellular delivery of macromolecular drugs. Drug Discov Today 8: 482-483.
Lienhardt C, Vernon A, and Raviglione MC (2010). New drugs and new regimens for the treatment of tuberculosis: Review of the drug development pipeline and implications for national programmes. Current Opinion in Pulmonary Medicine 16: 186-193.
Liua Y, Matsumotob M, Ishidac H, Ohguroc K, Yoshitakea M, Guptaa R, Geitera L, and Hafkin J (2018). Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Tuberculosis 111: 20-30.
Mahajan R (2013). Bedaquiline: First FDA-Approved Tuberculosis Drug in 40 Years. Int J Appl Basic Med Res 3: 1-2.
Metselaar JM, and Storm G (2005). Liposomes in the treatment of inflammatory disorders. Expert Opin. Drug Deliv 2: 465-76.
Moghassemia S and Hadjizadeh A (2014). Nano-niosomes as nanoscale drug delivery systems: An illustrated review. Journal of Controlled Release 185: 22-36.
Mohan A, D Kumar DP and Harikrishna J (2012). Newer anti-TB Drugs and Drug Delivery Systems. In Therapeutics, Medicine update, pp 388-392.
Muzzalupo R and Tavano L (2015). Niosomal drug delivery for transdermal targeting: recent advances. Research and Reports in Transdermal Drug Delivery 4: 23-33.
Nagda D, Rathore KS, Bharkatiya M, Sisodia SS, and Nema RK (2010). Bucky balls: A novel drug delivery system. Journal of Chemical and Pharmaceutical Research 2: 240 248.
Nasiruddin M, Neyaz MK, and Das S (2017). Nanotechnology-Based Approach in Tuberculosis Treatment. Tuberculosis Research and Treatment 2017: 1-12.
Olaru ID, Groote-Bidlingmaier FV, Heyckendorf J, Yew WW, Lange C and Chang KC (2015). Novel drugs against tuberculosis: A clinician’s perspective. European Respiratory Journal 45: 1119-1131.
Pandey R and Khuller GK (2006). Nanotechnology based drug delivery system(s) for the management of tuberculosis. Indian Journal of Experimental Biology 44: 357-366.
Pawar SN and Edgar KJ (2012). Alginate derivatization: A review of chemistry, properties and applications. Biomaterials 33: 3279-3305.
Rawal T and Butani S (2016). Combating Tuberculosis Infection: A Forbidding Challenge. Indian Journal of Pharmaceutical Sciences 78: 8-16.
Roy SD, Nandy S, and Banerjee S (2012). Microencapsulation: Convenient Mode of Drug Delivery in Novel Drug Delivery System. International Journal of Pharmacy and Life Sciences 3: 1555–1562.
Sacksteder KA, Protopopova M, Barry CE, Andries K and Nacy C (2012). A discovery and development of sq109: a new antitubercular drug with a novel mechanism of action. Future Microbiol 7: 823-837.
Sankhyan A and Pawar P (2012). Recent trends in Niosome as vesicular drug delivery system. Journal of Applied Pharma-ceutical Science 2: 20-32.
Shafiq N, Kondel R, and Malhotra S (2013). Tuberculosis and Nanotechnology: Where shall the Twain meet? Journal of Postgraduate Medicine Education and Research 47: pp. 188-192.
Smith JP (2011). Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis. Yale Journal of Biology and Medicine 84: 361-369.
Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, Fischer E, Barnes SW, Walker J R, Alland D, Barry CE and Boshoff, HI (2012). SQ109 targets mmpl3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of mycobacterium tuberculosis. Antimicrob Agents Chemother 56: 1797-1809.
Tiwari RK, Singh L, and Sharma V (2013). Alginate Micro-Beads in Novel Drug Delivery System: an Overview. International science press 5: 1-13.
Toosky M and Javid B (2014). Novel diagnostics and therapeutics for drug-resistant tuberculosis. British Medical Bulletin 110: 129-140.
Varun T, Sonia A, Bharat P, and Patil V (2012). Niosomes and liposomesVescicular approach towards Transdermal drug delivery. International journal of pharmaceutical and chemical sciences 1: 981-993.
Vashist A, Kaushik A, Vashist A, Jayant RD, Tomitaka A, Ahmad S, Gupta YK, and Nair M (2016). Recent trends on hydrogel based drug delivery systems for infectious diseases. Biomaterials Science 4: 1535-1553.
Vedha Hari BN, Chitra KP, Bhimavarapu R, Karunakaran P, Muthukrishnan M, and Rani BS (2010). Novel technologies: A weapon against tuberculosis. Indian Journal of Pharmacology 42: 338-344.
Zimmerman SC, and Lawless LJ (2001). Supramolecular Chemistry of Dendrimers. In Topics in Current Chemistry, Springer-Verlag Berlin Heidelberg, pp. 95-120.
Zumla A, Nahid P, Cole ST (2013). Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 12: 388-404.
